240 related articles for article (PubMed ID: 5571901)
1. The cardiovascular pharmacology of L(--)-dopa: peripheral and central effects.
Osborne MW; Wenger JJ; Willems W
J Pharmacol Exp Ther; 1971 Sep; 178(3):517-28. PubMed ID: 5571901
[No Abstract] [Full Text] [Related]
2. L-dopa: its effect on the cardiovascular system.
Carrasco HA; Lozano J; Lang TW; Meerbaum S
Geriatrics; 1971 Sep; 26(9):100-8. PubMed ID: 5125691
[No Abstract] [Full Text] [Related]
3. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
Watanabe AM; Parks LC; Kopin IJ
J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological study of pipratecol (JP 711) and of a pharmaceutical combination raubasine-JP 711].
Laubie M; Le Douarec JC
Arzneimittelforschung; 1969 Nov; 19(11):1820-6. PubMed ID: 4391788
[No Abstract] [Full Text] [Related]
5. Effects of L-dopa alone and in combination with dopa decarboxylase inhibitors on the arterial pressure and heart rate of dogs.
Minsker DH; Scriabine A; Stokes AL; Stone CA; Torchiana ML
Experientia; 1971 May; 27(5):529-31. PubMed ID: 5132586
[No Abstract] [Full Text] [Related]
6. Effects of L-dopa on myocardial contractile force: a reappraisal.
Wenger JJ; Osborne MW
Arch Int Pharmacodyn Ther; 1975 Oct; 217(2):251-6. PubMed ID: 1190920
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular function and halothane.
Goldberg AH
Clin Anesth; 1968; 1():23-60. PubMed ID: 4877407
[No Abstract] [Full Text] [Related]
8. [The effects of inotropic substances on the heart dynamics and peripheral blood circulation].
Schüren KP; Buschmann J; Meyer V; Schröder R
Verh Dtsch Ges Kreislaufforsch; 1968; 34():206-13. PubMed ID: 4899541
[No Abstract] [Full Text] [Related]
9. Cardiovascular effects of 1,1-dimethylhydrazine in the anesthetized dog. SAM-TR-65-56.
Britz WE
Tech Rep SAM-TR; 1965 Aug; ():1-12. PubMed ID: 5294884
[No Abstract] [Full Text] [Related]
10. The cardiovascular response to vertebral artery infusions of angiotensin in the dog.
Lowe RD; Scroop GC
Clin Sci; 1969 Dec; 37(3):593-603. PubMed ID: 4312145
[No Abstract] [Full Text] [Related]
11. Cardiovascular pharmacology of perhexiline.
Hudak WJ; Lewis RE; Kuhn WL
J Pharmacol Exp Ther; 1970 Jun; 173(2):371-82. PubMed ID: 4988496
[No Abstract] [Full Text] [Related]
12. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
Lotti VJ; Porter CC
J Pharmacol Exp Ther; 1970 Apr; 172(2):406-15. PubMed ID: 5441162
[No Abstract] [Full Text] [Related]
13. The effect of autonomic blocking agents on the cardiovascular response to etoxadrol (CL 1848). I. Ganglionic blockade.
Traber DL; Wilson RD; Praiano LL
Arch Int Pharmacodyn Ther; 1973 Aug; 204(2):333-41. PubMed ID: 4147881
[No Abstract] [Full Text] [Related]
14. Regional blood flow and cardiac responses to hydralazine.
Spokas EG; Wang HH
J Pharmacol Exp Ther; 1980 Feb; 212(2):294-303. PubMed ID: 7351643
[No Abstract] [Full Text] [Related]
15. Cardiovascular effects of orciprenaline (Alupent) inhalation and prednisolone.
Prasad K; Szabo L
Adv Myocardiol; 1980; 1():437-52. PubMed ID: 7394342
[No Abstract] [Full Text] [Related]
16. The role of brain 5-hydroxytryptamine in the central action of L-DOPA.
Maj J; Pawlowski L; Sarnek J
Adv Biochem Psychopharmacol; 1974; 10():253-6. PubMed ID: 4846541
[No Abstract] [Full Text] [Related]
17. Effects of oleandrin on cardiovascular hemodynamics in the dog.
Deavers SI; Rosborough JP; Hoff HE; McCrady JD
Am J Vet Res; 1979 Oct; 40(10):1421-5. PubMed ID: 575023
[No Abstract] [Full Text] [Related]
18. Cardiovascular effects of glucagon in the intact anesthetized and hepatectomized dog.
Pappas G; Guillen J; Aldrete JA
Surgery; 1970 Aug; 68(2):363-8. PubMed ID: 5450717
[No Abstract] [Full Text] [Related]
19. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.
Hahn RA; Wardell JR; Sarau HM; Ridley PT
J Pharmacol Exp Ther; 1982 Nov; 223(2):305-13. PubMed ID: 6127401
[TBL] [Abstract][Full Text] [Related]
20. Studies on the cardiovascular effects of synthetic vasopressin.
Nakano J
J Pharmacol Exp Ther; 1967 Jul; 157(1):19-31. PubMed ID: 6029485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
